Physician profile
Brandi Plummer
NPI 1023697265
$4,039.52
in general payments reported to CMS, 2019-2025
24 companies · $1,293 in 2025
The $1,293 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $187 · 2023: $746 · 2024: $1,813 · 2025: $1,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,852.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $479.53 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $476.55 | 2022-2025 | Repatha, Evenity, Prolia |
| Abbvie INC. | $454.72 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $430.90 | 2022-2025 | |
| Novo Nordisk INC | $426.94 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.60 | 2023-2025 | Jardiance |
| Dexcom, INC. | $254.46 | 2024-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $230.13 | 2023-2025 | |
| Lilly USA, LLC | $213.48 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $157.99 | 2023-2025 | Arexvy, Shingrix |
| Daiichi Sankyo INC. | $133.93 | 2024-2025 | Injectafer |
| Axsome Therapeutics, INC. | $73.29 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.07 | 2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $64.69 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $57.51 | 2023-2025 | Verquvo, Gardasil 9, Capvaxive |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $45.39 | 2023-2025 | Contrave, Nexlizet, Nexletol |
| Idorsia Pharmaceuticals US INC | $35.80 | 2023 | Quviviq |
| Exact Sciences Corporation | $32.07 | 2025 | The Cologuard Plus Collection Kit |
| Radius Health, INC. | $24.66 | 2025 | Tymlos |
| Abbott Laboratories | $20.28 | 2024 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $18.71 | 2025 | Nexletol |
| Masimo Corporation | $18.31 | 2023 | Set and Rainbow Set, Emma and Isa, Rainbow Acoustic Monitoring |
| Boston Scientific Corporation | $16.83 | 2024 | Watchman Flx |
| Corcept Therapeutics | $16.68 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandi Plummer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.